Oligonucleotide Deal Benchmarks in Rare Disease

Median Upfront

$468M

Range: $229M - $706M

Total Deal Value

$2.5B

Range: $1.5B - $3.6B

Royalty Rate

8.3% - 16.5%

Tiered up to 20.5%

Dev Milestones

$452M

Range: $271M - $633M

Model Your Deal

Market Analysis

Oligonucleotide therapies in rare disease have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 oligonucleotide asset in rare disease is $468M, with total deal values reaching $2.5B. Development milestones average $452M, while regulatory milestones contribute $514M.

The rare disease oligonucleotide landscape is characterized by limited competitive intensity per indication but growing platform competition. Gene therapies and oligonucleotide-based approaches are transforming treatment paradigms, with orphan designations enabling premium pricing and accelerated regulatory paths. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for oligonucleotide rare disease deals range from 8.3% to 16.5% at the base tier, with tiered escalation reaching 12.3%-20.5% on blockbuster sales. Commercial milestones averaging $1.1B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a oligonucleotide rare disease licensing deal?

Based on our analysis, Phase 2 oligonucleotide licensing deals in rare disease average $468M in upfront payments, with a range of $229M to $706M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for oligonucleotide rare disease transactions?

The median total deal value for Phase 2 oligonucleotide assets in rare disease is $2.5B, ranging from $1.5B to $3.6B. This includes development milestones ($452M), regulatory milestones ($514M), and commercial milestones ($1.1B).

What royalty rates are standard for oligonucleotide deals in rare disease?

Base royalty rates for oligonucleotide rare disease transactions range from 8.3% to 16.5%, with tiered escalations reaching 12.3%-20.5% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in oligonucleotide rare disease deals?

Oligonucleotide rare disease deals allocate approximately 81% of total deal value to milestones. Development milestones ($452M) make up the largest share, followed by commercial milestones ($1.1B) and regulatory milestones ($514M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

Gene Therapy in Rare Disease

View

Small Molecule in Rare Disease

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating